Clinical Trial: BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07544160) titled 'BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)' on April 08.

Brief Summary: This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.

Study Start Date: April 07

Study Type: INTERVENTIONAL

Condition: Inflammatory Bowel Diseases (IBD)

Intervention: BIOLOGICAL: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T

Anti-BCMA, Anti-CD19 Compound CAR-T cells

Recruitment Status: NOT_YET_RECRUITING

Sponsor: iCel...